Kobayashi Pharmaceutical Co., Ltd.
KBYPF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $291 | $36,411 | $32,607 | $51,141 |
| % Growth | -99.2% | 11.7% | -36.2% | – |
| Cost of Goods Sold | $140 | $16,949 | $15,924 | $26,234 |
| Gross Profit | $151 | $19,462 | $16,683 | $24,907 |
| % Margin | 52% | 53.5% | 51.2% | 48.7% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | -$14,534 |
| SG&A Expenses | $118 | $15,293 | $14,203 | $2,335 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $16,869 |
| Other Operating Expenses | $0 | $56 | -$55 | $14,688 |
| Operating Expenses | $118 | $15,349 | $14,148 | $17,023 |
| Operating Income | $33 | $4,113 | $2,535 | $7,884 |
| % Margin | 11.3% | 11.3% | 7.8% | 15.4% |
| Other Income/Exp. Net | $1 | -$1,607 | -$792 | -$1,249 |
| Pre-Tax Income | $34 | $2,506 | $1,743 | $6,635 |
| Tax Expense | $9 | $965 | $120 | $1,909 |
| Net Income | $25 | $1,543 | $1,624 | $4,723 |
| % Margin | 8.5% | 4.2% | 5% | 9.2% |
| EPS | 0.33 | 20.76 | 21.85 | 63.53 |
| % Growth | -98.4% | -5% | -65.6% | – |
| EPS Diluted | 0.33 | 20.76 | 21.85 | 63.53 |
| Weighted Avg Shares Out | 74 | 74 | 74 | 74 |
| Weighted Avg Shares Out Dil | 74 | 74 | 74 | 74 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $392 | $53 | $48 |
| Interest Expense | $0 | $0 | $0 | $5 |
| Depreciation & Amortization | $15 | $2,156 | $2,006 | $2,006 |
| EBITDA | $49 | $6,325 | $4,486 | $8,646 |
| % Margin | 16.7% | 17.4% | 13.8% | 16.9% |